Medical Cannabis State and Federal Regulations

Abstract

Thirty-six states and four territories in the United States have legalized cannabis for medical and/or recreational use. Marijuana, however, continues to be classified as a schedule I substance under the Federal Controlled Substance Act and remains illegal under US federal law. The incongruity between state and federal legislation creates various challenges for stakeholders: patients, medical trainees, providers, and health care institutions. This communication provides an overview of the major policies impacting Cannabis sativa use within the United States, various state and federal regulations, and highlights potential implications for health care institutions moving forward. Existing literature, regulations, and policies on medical marijuana (MMJ) use in health care settings were searched, reviewed, analyzed, and distilled. As a consequence of legislative inconsistencies, there is insufficient clarity and resultant challenges regarding MMJ usage, prescription, possession, education, and research-related policies for health care stakeholders across the United States. Coupled with limited scientific evidence on the clinical efficacy of MMJ, the needs of the patient and the quality of health care delivery may be affected as hospitals balance the competing risks of being legislatively compliant while protecting the rights of patients and health care employees. There is a recognized need to better define acceptable MMJ policies and regulations in health care settings that are evidence-based, legally compliant, and adequately address the needs of both patients and providers. Given the complexity of the legal and policy landscape, there are potential opportunities for improvement, including in medical education and training, research, and usage oversight of MMJ for stakeholders in the United States.

Argentination: A Silver Bullet for Cannabinoid Separation by Differential Mobility Spectrometry

“…With recreational cannabis becoming legalized in more parts of the world, governing bodies are implementing new regulations by which commercial growers must abide. 1,2 For example, cannabis products sold in Canada must state the quantity of Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) contained within the product either as purchased (e.g., edibles) or once activated by combustion (dried cannabis). This information is important for quality control purposes and is invaluable to the consumer, 3 especially to new users who may be unaware of their tolerance for each cannabinoid.…”

Studi Komparasi antara Rumah Sakit Berbadan Hukum Yayasan dengan Rumah Sakit Berbadan Hukum Perseroan Terbatas

“…Keuntungan yang diperoleh dari operasi rumah sakit berbadan hokum perseroan terbatas cenderung untuk memenuhi kepentingan finansial pemilik atau pemegang saham, dengan sebagian mungkin dialokasikan untuk pengembangan perusahaan atau pembagian dividen kepada pemegang saham, mengembangkan bisnis, atau meningkatkan nilai perusahaan. Tingkat transparansi mungkin bervariasi tergantung pada kebijakan perusahaan (Perlman, 2021). Meskipun rumah sakit PT juga harus mematuhi peraturan yang berlaku, fokus utamanya adalah pada kesehatan keuangan perusahaan.…”

A new approach to treating sleep disorders? - Medical marijuana review

“…Despite cannabis being legalized for medical use across various regions in the US, the clinical evidence backing its effectiveness for certain conditions is still not comprehensive [27,28]. This study aimed to explore the impact of obtaining a medical marijuana card on clinical outcomes and symptoms of cannabis use disorder in adults with main complaints of chronic pain, insomnia, or anxiety/depression.…”